AstraZeneca Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer Ruchika Sharma4 April 2025 3:30 PM ISTCambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been approved in the European Union...
AstraZeneca gets USFDA approval for perioperative Imfinzi for bladder cancer Ruchika Sharma1 April 2025 2:15 PM ISTImfinzi was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings.
AstraZeneca Imfinzi approved in EU for limited stage small cell lung cancer Ruchika Sharma17 March 2025 10:30 AM ISTThe safety profile for Imfinzi was generally manageable and consistent with the known profile of this medicine.
AstraZeneca Pharma India secures CDSCO nod to import, sell Durvalumab for small cell lung cancer Ruchika Sharma8 March 2025 2:30 PM ISTBangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation...
AstraZeneca Imfinzi based perioperative regimen recommended for approval in EU for resectable non-small cell lung cancer Ruchika Sharma4 March 2025 10:15 AM ISTAstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for...
CDSCO nod to AstraZeneca Pharma India to import, sell lung cancer treatment medicine Ruchika Sharma3 March 2025 4:26 PM ISTAstraZeneca Pharma India has announced that the Company has received permission from the CentralDrugs Standard Control Organisation, Directorate...
AstraZeneca Imfinzi granted priority review by USFDA for muscle-invasive bladder cancer Ruchika Sharma7 Dec 2024 12:30 PM ISTCambridge: AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and granted Priority Review...
AstraZeneca Imfinzi gets USFDA nod for limited-stage small cell lung cancer Ruchika Sharma6 Dec 2024 11:00 AM ISTAstraZeneca's Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer...
Imfinzi, Lynparza combo approved in EU for mismatch repair proficient advanced or recurrent endometrial cancer: AstraZeneca Ruchika Sharma18 Aug 2024 10:00 AM ISTCambridge: AstraZeneca's Imfinzi (durvalumab) and Lynparza (olaparib) have been approved in the European Union (EU) as treatment for certain...
AstraZeneca Imfinzi in combo with chemotherapy gets USFDA approval for treatment of resectable non-small cell lung cancer before and after surgery Ruchika Sharma17 Aug 2024 1:30 PM ISTCambridge: AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult...
AstraZeneca Imfinzi gets USFDA priority review for limited-stage small cell lung cancer Ruchika Sharma16 Aug 2024 12:30 PM ISTCambridge: AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), based on the results from the positive...
FDA Advisory Committee reviewed Imfinzi for resectable non-small cell lung cancer based on AEGEAN Phase III trial results Ruchika Sharma28 July 2024 4:15 PM ISTThe Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has acknowledged that AstraZeneca's Imfinzi (durvalumab) met...
